Stifel Financial’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Stifel Financial’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-43,773	Closed	-$197K	–	3533
2021 Q4	$197K	Sell	43,773 -69,799	-61%	-$331K	﹤0.01%	3156
2021 Q3	$552K	Sell	113,572 -27,644	-20%	-$152K	﹤0.01%	2525
2021 Q2	$963K	Sell	141,216 -22,577	-14%	-$183K	﹤0.01%	2135
2021 Q1	$1.16M	Sell	163,793 -34,093	-17%	-$246K	﹤0.01%	1896
2020 Q4	$1.24M	Sell	197,886 -17,334	-8%	-$102K	﹤0.01%	1696
2020 Q3	$1.16M	Sell	215,220 -2,903	-1%	-$14.4K	﹤0.01%	1531
2020 Q2	$1.14M	Sell	218,123 -58,950	-21%	-$262K	﹤0.01%	1469
2020 Q1	$872K	Buy	277,073 +59,909	+28%	+$221K	﹤0.01%	1519
2019 Q4	$874K	Buy	217,164 +68,644	+46%	+$238K	﹤0.01%	1926
2019 Q3	$637K	Sell	148,520 -45,202	-23%	-$181K	﹤0.01%	2029
2019 Q2	$774K	Buy	193,722 +85,372	+79%	+$406K	﹤0.01%	1963
2019 Q1	$578K	Buy	108,350 +90,850	+519%	+$587K	﹤0.01%	1980
2018 Q4	$90K	Buy	+17,500	New	+$133K	﹤0.01%	2571

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Stifel Financial's PRTK Position: Q1 2022 in Review

Stifel Financial sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 43,773 shares — an estimated $197K sold.

Stifel Financial first reported a position in PRTK in Q4 2018 and held it in 13 quarters. The position peaked at $1.24M in Q4 2020. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

Stifel Financial reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Stifel Financial sold 43,773 Paratek Pharmaceuticals, Inc. shares in Q1 2022, an estimated $197K.
Stifel Financial first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2018 and held it in 13 quarters.
Stifel Financial's Paratek Pharmaceuticals, Inc. position peaked at $1.24M in Q4 2020.
100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Stifel Financial's 13F filing for Q1 2022, filed 13 May 2022.